Join us for a dynamic panel discussion exploring the evolution of investment in medical and healthcare interventions designed to advance health equity. In a competitive market, focus on equity during the journey from molecule to product does not have to conflict with other priorities. This session will explore how founders and business development professionals can drive innovation while tackling some of the world’s most persistent health disparities. Together we will explore: -Finding novel targets: Reimagining drug discovery with emerging tools that aim to eliminate biased research -Developing paradigm shifting drugs: Reexamining drug candidate selection and clinical trial designs for broad impact -Expanding patient access: Pushing towards precision medicine and the modalities / tools that make those solutions scalable -Driving investor return: Framing the case for investment in therapies and teams that fall outside of the traditional frame